Patients with head and neck cancer undergoing radiation therapy are less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, according to a study led by radiation oncologists at Roswell Park Comprehensive Cancer Center.
A collaborative research team led by scientists from Roswell Park Comprehensive Cancer Center and Wake Forest University Baptist Medical Center has determined that a GTPase called RAC1 actively recruits enzymes involved in nucleotide production to promote cancer metastasis.
